Arcturus Therapeutics Holdings Stock Performance
| ARCT Stock | USD 17.51 0.58 3.43% |
The firm shows a Beta (market volatility) of 1.33, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arcturus Therapeutics will likely underperform. At this point, Arcturus Therapeutics has a negative expected return of -0.2%. Please make sure to confirm Arcturus Therapeutics' potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Arcturus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Arcturus Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 3.43 | Five Day Return 2.94 | Year To Date Return (47.08) | Ten Year Return (32.39) | All Time Return (66.87) |
Last Split Factor 1:7 | Dividend Date 2017-11-16 | Last Split Date 2017-11-16 |
1 | Japans Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 St... | 09/13/2024 |
2 | Disposition of 12000 shares by Chivukula Pad of Arcturus Therapeutics at 20.7601 subject to Rule 16b-3 | 10/15/2024 |
3 | Arcturus Therapeutics executive sells 249,121 in stock | 10/17/2024 |
4 | Arcturus Therapeutics Stock Price Down 6.1 percent Heres Why | 10/24/2024 |
5 | Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 | 10/31/2024 |
6 | Arcturus Therapeutics Holdings Inc. Given Consensus Recommendation of Buy by Brokerages | 11/05/2024 |
7 | Arcturus Therapeutics Holdings Inc Q3 2024 Earnings Report Preview What To Look For | 11/06/2024 |
8 | Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress | 11/07/2024 |
9 | Arcturus Therapeutics Holdings Inc Q3 2024 Earnings Call Highlights Strategic Advances ... | 11/08/2024 |
10 | Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial | 11/11/2024 |
11 | Acquisition by Marantz Jing L. of 11869 shares of Arcturus Therapeutics at 34.92 subject to Rule 16b-3 | 11/26/2024 |
| Begin Period Cash Flow | 394 M |
Arcturus |
Arcturus Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,110 in Arcturus Therapeutics Holdings on August 30, 2024 and sell it today you would lose (359.00) from holding Arcturus Therapeutics Holdings or give up 17.01% of portfolio value over 90 days. Arcturus Therapeutics Holdings is currently does not generate positive expected returns and assumes 4.1862% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Arcturus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arcturus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcturus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arcturus Therapeutics Holdings, and traders can use it to determine the average amount a Arcturus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0487
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ARCT |
Estimated Market Risk
| 4.19 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arcturus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arcturus Therapeutics by adding Arcturus Therapeutics to a well-diversified portfolio.
Arcturus Therapeutics Fundamentals Growth
Arcturus Stock prices reflect investors' perceptions of the future prospects and financial health of Arcturus Therapeutics, and Arcturus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcturus Stock performance.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 250.83 M | ||||
| Shares Outstanding | 27.09 M | ||||
| Price To Earning | 119.50 X | ||||
| Price To Book | 1.75 X | ||||
| Price To Sales | 2.96 X | ||||
| Revenue | 157.75 M | ||||
| Gross Profit | 62.95 M | ||||
| EBITDA | (24.17 M) | ||||
| Net Income | (29.73 M) | ||||
| Cash And Equivalents | 283.49 M | ||||
| Cash Per Share | 10.67 X | ||||
| Total Debt | 30.22 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 3.14 X | ||||
| Book Value Per Share | 9.67 X | ||||
| Cash Flow From Operations | (18.1 M) | ||||
| Earnings Per Share | (2.33) X | ||||
| Market Capitalization | 474.3 M | ||||
| Total Asset | 429.4 M | ||||
| Retained Earnings | (367.87 M) | ||||
| Working Capital | 304.6 M | ||||
| Current Asset | 54.55 M | ||||
| Current Liabilities | 3.52 M | ||||
About Arcturus Therapeutics Performance
Assessing Arcturus Therapeutics' fundamental ratios provides investors with valuable insights into Arcturus Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arcturus Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.11) | (0.11) |
Things to note about Arcturus Therapeutics performance evaluation
Checking the ongoing alerts about Arcturus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcturus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcturus Therapeutics generated a negative expected return over the last 90 days | |
| Arcturus Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 157.75 M. Net Loss for the year was (29.73 M) with profit before overhead, payroll, taxes, and interest of 62.95 M. | |
| Arcturus Therapeutics Holdings currently holds about 283.49 M in cash with (18.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.67. | |
| Arcturus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Marantz Jing L. of 11869 shares of Arcturus Therapeutics at 34.92 subject to Rule 16b-3 |
- Analyzing Arcturus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcturus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Arcturus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcturus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcturus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcturus Therapeutics' stock. These opinions can provide insight into Arcturus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.